Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor I was pleased to see pictures of hydroxychloroquine toxicity in the recent Ophthalmic Images,1 as a reminder that the problem still exists. However, some readers may draw an erroneous impression from the caption, which suggests that fundus autofluorescence may “be useful to determine whether patients with macular pigmentary change may continue using hydroxychloroquine.”
Marmor MF. Fundus Autofluorescence Is Not the Best Early Screen for Hydroxychloroquine Toxicity. JAMA Ophthalmol. 2013;131(11):1487-1488. doi:10.1001/jamaophthalmol.2013.4835